Citadel Advisors’s 4D Molecular Therapeutics FDMT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $713K | Sell |
192,239
-138,972
| -42% | -$516K | ﹤0.01% | 3659 |
|
|
2025
Q1 | $1.07M | Sell |
331,211
-273,881
| -45% | -$885K | ﹤0.01% | 3209 |
|
|
2024
Q4 | $3.37M | Buy |
605,092
+477,444
| +374% | +$2.66M | ﹤0.01% | 2121 |
|
|
2024
Q3 | $1.38M | Buy |
127,648
+54,450
| +74% | +$589K | ﹤0.01% | 2822 |
|
|
2024
Q2 | $1.54M | Sell |
73,198
-15,031
| -17% | -$316K | ﹤0.01% | 2677 |
|
|
2024
Q1 | $2.81M | Buy |
88,229
+69,671
| +375% | +$2.22M | ﹤0.01% | 2202 |
|
|
2023
Q4 | $376K | Sell |
18,558
-124,662
| -87% | -$2.53M | ﹤0.01% | 4022 |
|
|
2023
Q3 | $1.82M | Buy |
143,220
+124,335
| +658% | +$1.58M | ﹤0.01% | 2472 |
|
|
2023
Q2 | $341K | Buy |
18,885
+14,013
| +288% | +$253K | ﹤0.01% | 3991 |
|
|
2023
Q1 | $83.8K | Buy |
+4,872
| New | +$83.8K | ﹤0.01% | 4982 |
|
|
2022
Q4 | – | Sell |
-122,459
| Closed | -$984K | – | 6224 |
|
|
2022
Q3 | $984K | Sell |
122,459
-102,483
| -46% | -$823K | ﹤0.01% | 3432 |
|
|
2022
Q2 | $1.57M | Buy |
224,942
+176,409
| +363% | +$1.23M | ﹤0.01% | 2965 |
|
|
2022
Q1 | $733K | Buy |
48,533
+16,656
| +52% | +$252K | ﹤0.01% | 4041 |
|
|
2021
Q4 | $700K | Buy |
31,877
+18,041
| +130% | +$396K | ﹤0.01% | 4238 |
|
|
2021
Q3 | $373K | Sell |
13,836
-13,476
| -49% | -$363K | ﹤0.01% | 4824 |
|
|
2021
Q2 | $658K | Buy |
27,312
+7,696
| +39% | +$185K | ﹤0.01% | 4456 |
|
|
2021
Q1 | $851K | Sell |
19,616
-32,847
| -63% | -$1.43M | ﹤0.01% | 4078 |
|
|
2020
Q4 | $2.18M | Buy |
+52,463
| New | +$2.18M | ﹤0.01% | 2482 |
|